Trials / Not Yet Recruiting
Not Yet RecruitingNCT06898060
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
A Multicenter, Randomized, Open-label, Parallel Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 282 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLG2128 | Recommended dosage is 80 μg subcutaneously once daily，52week |
| DRUG | Teriparatide Injection | Recommended dosage is 20μg subcutaneously once daily，52week |
Timeline
- Start date
- 2025-06-01
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2025-03-27
- Last updated
- 2025-03-27
Source: ClinicalTrials.gov record NCT06898060. Inclusion in this directory is not an endorsement.